DK2041123T3 - Kondenserede cykliske forbindelser. - Google Patents

Kondenserede cykliske forbindelser.

Info

Publication number
DK2041123T3
DK2041123T3 DK07767983.5T DK07767983T DK2041123T3 DK 2041123 T3 DK2041123 T3 DK 2041123T3 DK 07767983 T DK07767983 T DK 07767983T DK 2041123 T3 DK2041123 T3 DK 2041123T3
Authority
DK
Denmark
Prior art keywords
cyclic compounds
condensed cyclic
condensed
compounds
cyclic
Prior art date
Application number
DK07767983.5T
Other languages
Danish (da)
English (en)
Inventor
Tsuneo Yasuma
Nobuyuki Negoro
Masayuki Yamashita
Masahiro Itou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK2041123T3 publication Critical patent/DK2041123T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
DK07767983.5T 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser. DK2041123T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006177099 2006-06-27
PCT/JP2007/063208 WO2008001931A2 (en) 2006-06-27 2007-06-26 Fused cyclic compounds

Publications (1)

Publication Number Publication Date
DK2041123T3 true DK2041123T3 (da) 2012-05-07

Family

ID=38656568

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10172951.5T DK2248812T5 (da) 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser som GPR40-receptormodulatorer
DK07767983.5T DK2041123T3 (da) 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10172951.5T DK2248812T5 (da) 2006-06-27 2007-06-26 Kondenserede cykliske forbindelser som GPR40-receptormodulatorer

Country Status (36)

Country Link
US (5) US7732626B2 (enExample)
EP (4) EP2041123B9 (enExample)
JP (3) JP4401428B2 (enExample)
KR (1) KR101058772B1 (enExample)
CN (4) CN103083307A (enExample)
AR (1) AR061644A1 (enExample)
AT (1) ATE543815T1 (enExample)
AU (1) AU2007265966B2 (enExample)
BR (1) BRPI0713378A8 (enExample)
CA (2) CA2838448A1 (enExample)
CL (1) CL2007001873A1 (enExample)
CO (1) CO6160234A2 (enExample)
CR (1) CR10564A (enExample)
CY (2) CY1112705T1 (enExample)
DK (2) DK2248812T5 (enExample)
ES (2) ES2450081T3 (enExample)
GE (1) GEP20115359B (enExample)
HR (2) HRP20120333T1 (enExample)
IL (1) IL195947A (enExample)
JO (1) JO2969B1 (enExample)
MA (1) MA30537B1 (enExample)
ME (1) ME00535B (enExample)
MX (1) MX2008016274A (enExample)
MY (1) MY154798A (enExample)
NO (1) NO20090235L (enExample)
NZ (1) NZ574038A (enExample)
PE (1) PE20080993A1 (enExample)
PL (2) PL2248812T3 (enExample)
PT (2) PT2041123E (enExample)
RS (2) RS52307B (enExample)
RU (1) RU2444521C2 (enExample)
SI (2) SI2041123T1 (enExample)
TW (1) TWI354668B (enExample)
UA (1) UA95296C2 (enExample)
WO (1) WO2008001931A2 (enExample)
ZA (1) ZA200900154B (enExample)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2205548A1 (en) 2007-10-10 2010-07-14 Amgen, Inc Substituted biphenyl gpr40 modulators
CA2716352C (en) * 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8586607B2 (en) 2008-07-28 2013-11-19 Syddansk Universitet Compounds for the treatment of metabolic diseases
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010076884A1 (ja) 2008-12-29 2010-07-08 武田薬品工業株式会社 新規縮合環化合物およびその用途
AR075158A1 (es) 2009-01-27 2011-03-16 Takeda Pharmaceutical Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
US20120035196A1 (en) 2009-04-22 2012-02-09 Kenji Negoro Carboxylic acid compound
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
AU2010279171A1 (en) 2009-07-28 2012-03-01 Takeda Pharmaceutical Company Limited Tablet
EP2495238A4 (en) 2009-10-30 2013-04-24 Mochida Pharm Co Ltd NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
TW201206911A (en) 2010-04-27 2012-02-16 Takeda Pharmaceutical Bicyclic compound
BR112012032055B8 (pt) 2010-06-16 2019-11-12 Takeda Pharmaceuticals Co cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-benzimidazol-2-carboxamida, medicamento, e, uso do cristal
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5816626B2 (ja) 2010-09-17 2015-11-18 武田薬品工業株式会社 糖尿病治療剤
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
AR084032A1 (es) 2010-11-30 2013-04-17 Takeda Pharmaceutical Compuesto biciclico
AR084050A1 (es) 2010-12-01 2013-04-17 Boehringer Ingelheim Int Acidos indaniloxidihidrobenzofuranilaceticos
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AU2012218401A1 (en) 2011-02-17 2013-09-05 Takeda Pharmaceutical Company Limited Production method of optically active dihydrobenzofuran derivative
WO2012136221A1 (en) 2011-04-08 2012-10-11 Syddansk Universitet Ortho-fluoro substituted compounds for the treatment of metabolic diseases
JP5420796B2 (ja) 2011-04-27 2014-02-19 持田製薬株式会社 新規３−ヒドロキシイソチアゾール１−オキシド誘導体
CA2834465A1 (en) 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103012343B (zh) * 2011-09-26 2015-04-08 上海恒瑞医药有限公司 稠合环类衍生物、其制备方法及其在医药上的应用
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JPWO2013061962A1 (ja) 2011-10-24 2015-04-02 武田薬品工業株式会社 二環性化合物
CN103429581B (zh) 2012-01-12 2015-08-26 江苏恒瑞医药股份有限公司 多环类衍生物、其制备方法及其在医药上的应用
EP2802571A1 (en) 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
GB2498968A (en) * 2012-02-01 2013-08-07 Prosidion Ltd Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013122028A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
JP6077555B2 (ja) 2012-02-15 2017-02-08 武田薬品工業株式会社 錠剤
CN104254525B (zh) * 2012-02-24 2016-05-25 武田药品工业株式会社 芳环化合物
NZ631569A (en) 2012-02-28 2016-10-28 Piramal Entpr Ltd Phenyl alkanoic acid derivatives as gpr agonists
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US9073864B2 (en) 2012-03-29 2015-07-07 Takeda Pharmaceutical Company Limted Aromatic ring compound
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
JPWO2013168760A1 (ja) 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
EP2854772A1 (en) 2012-06-05 2015-04-08 Takeda Pharmaceutical Company Limited Solid preparation
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
SI2894151T1 (sl) 2012-09-04 2021-01-29 Shanghai Hengrui Pharmaceutical Co. Ltd. Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
WO2014078610A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
CA2889783A1 (en) 2012-11-28 2014-06-05 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2953681B1 (en) 2013-02-06 2017-03-15 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014133361A1 (ko) * 2013-02-28 2014-09-04 에스케이케미칼주식회사 삼환식 화합물 및 이의 용도
CN103145663B (zh) * 2013-03-01 2016-03-23 上海高准医药有限公司 (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
CN104059039B (zh) * 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
WO2014170842A2 (en) 2013-04-17 2014-10-23 Piramal Enterprises Limited Substituted alkyl carboxylic acid derivatives as gpr agonists
CN104870429B (zh) * 2013-05-22 2017-05-03 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
CN104250238B (zh) * 2013-06-25 2017-12-26 南京圣和药业股份有限公司 Gpr40激动剂及其应用
CN104250239B (zh) * 2013-06-29 2016-09-07 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104507921B (zh) * 2013-07-02 2017-02-22 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
CN105358544A (zh) 2013-07-09 2016-02-24 武田药品工业株式会社 杂环化合物
SI3031799T1 (en) 2013-08-09 2018-07-31 Takeda Pharmaceutical Company Limited Aromatic compound
CN104370864B (zh) * 2013-08-14 2016-04-13 成都苑东生物制药股份有限公司 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法
CN105246875A (zh) * 2013-09-03 2016-01-13 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015062486A1 (en) * 2013-10-31 2015-05-07 Sunshine Lake Pharma Co., Ltd. Biphenyl compounds and uses thereof
EA201690888A1 (ru) 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
KR101728900B1 (ko) 2014-10-17 2017-04-24 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체 및 다른 유효성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
CN105418563B (zh) * 2015-12-28 2017-11-10 山东大学 Tak‑875类似物及其制备方法与应用
EP3436003B1 (en) 2016-03-29 2023-08-23 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2018138029A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138030A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7049349B2 (ja) 2017-01-26 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
US10550127B1 (en) 2017-02-08 2020-02-04 Boehringer Ingelheim International Gmbh Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3604267A4 (en) 2017-03-31 2020-12-16 Takeda Pharmaceutical Company Limited Aromatic compound
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
US11225471B2 (en) 2017-11-16 2022-01-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
JP7289305B2 (ja) 2018-01-08 2023-06-09 セロン ファーマ エス．アー． Ｇｐｒ４０アゴニストとしての３－フェニル－４－ヘキシン酸誘導体
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN110294744A (zh) * 2018-03-21 2019-10-01 中国医学科学院药物研究所 Gpr40受体激动剂、其制法和其药物组合物与用途
IL277495B2 (en) 2018-03-23 2024-08-01 Carmot Therapeutics Inc Modulators of protein-coupled receptors - G
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
EP3650440A4 (en) 2018-08-27 2020-11-25 Scohia Pharma, Inc. BENZOIC ESTER COMPOUND
EP3856768A2 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
JP7511548B2 (ja) 2018-09-24 2024-07-05 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US20220071925A1 (en) * 2019-02-13 2022-03-10 Gexval Inc. Medicinal composition for preventing or treating bone diseases
WO2020166662A1 (ja) * 2019-02-13 2020-08-20 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
CN119874775A (zh) 2020-02-07 2025-04-25 加舒布鲁姆生物公司 杂环glp-1激动剂
PH12022552562A1 (en) 2020-03-25 2022-12-19 Takeda Pharmaceuticals Co Qd dosing of gip receptor agonist peptide compounds and uses thereof
JP2023524603A (ja) 2020-03-25 2023-06-12 武田薬品工業株式会社 Ｇｉｆ受容体アゴニストペプチド化合物及びその使用
JP7748104B2 (ja) * 2020-08-12 2025-10-02 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
US20240067603A1 (en) * 2020-12-16 2024-02-29 Regents Of The University Of Minnesota Cubanyl biguanide compounds
EP4337682A2 (en) 2021-05-13 2024-03-20 Carmot Therapeutics Inc. Modulators of g-protein coupled receptors
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4634180A1 (en) 2022-12-15 2025-10-22 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
WO2025006921A1 (en) 2023-06-30 2025-01-02 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AR133241A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
WO2025015268A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulators of calcitonin receptor and/or amylin receptor activity
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN117865851A (zh) * 2024-01-10 2024-04-12 上海吉奉生物科技有限公司 一种Fmoc-2,6-二甲基酪氨酸的合成方法
WO2025154020A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
US5489586A (en) 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
US5612330A (en) 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
RU6023U1 (ru) 1997-01-20 1998-02-16 АО "Автоэлектроника" Устройство управления для экономайзера принудительного холостого хода
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
NZ515087A (en) 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
RU11297U1 (ru) 1999-06-16 1999-09-16 Курзанов Евгений Владимирович Установка для выборочного измерения производительности нефтяных источников при групповом учете
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
IL148084A0 (en) 1999-08-26 2002-09-12 Aventis Pharm Prod Inc Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
EP1457490A1 (en) 1999-11-10 2004-09-15 Takeda Chemical Industries, Ltd. 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
CA2395414A1 (en) * 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd Condensed purine derivative
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
RU2340611C2 (ru) 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002068471A2 (en) 2000-12-21 2002-09-06 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide
AP2003002825A0 (en) 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
NZ528406A (en) 2001-03-30 2004-03-26 Pfizer Prod Inc Pyridazinone aldose reductase inhibitors
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
TW522326B (en) * 2001-08-03 2003-03-01 Inventec Corp Real-time data customer service system and method thereof
US6701066B2 (en) * 2001-10-11 2004-03-02 Micron Technology, Inc. Delivery of solid chemical precursors
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
JP4166024B2 (ja) 2002-03-07 2008-10-15 独立行政法人科学技術振興機構 ２環式化合物およびその製造方法
WO2003095438A1 (en) 2002-04-26 2003-11-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
AU2003252697A1 (en) * 2002-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Cell differentiation inductor
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
WO2004080943A1 (ja) * 2003-03-11 2004-09-23 Ono Pharmaceutical Co., Ltd. シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
RU2353617C2 (ru) 2003-10-31 2009-04-27 Такеда Фармасьютикал Компани Лимитед Производные пиридина в качестве ингибиторов дипептидилпептидазы iv
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
WO2005063729A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) * 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
JP3689711B1 (ja) 2004-12-24 2005-08-31 極東鋼弦コンクリート振興株式会社 真空グラウト注入方法
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
CA2598934A1 (en) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
TW200811170A (en) * 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
PE20080212A1 (es) * 2006-06-27 2008-04-25 Sanofi Aventis Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1)
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I

Also Published As

Publication number Publication date
RS52307B (sr) 2012-12-31
PT2248812E (pt) 2014-03-12
CA2656003C (en) 2014-03-25
CN103070854A (zh) 2013-05-01
CN102731451A (zh) 2012-10-17
CN101616913A (zh) 2009-12-30
MY154798A (en) 2015-07-31
NZ574038A (en) 2011-12-22
AU2007265966A1 (en) 2008-01-03
HRP20140201T1 (hr) 2014-04-11
EP2248812B1 (en) 2013-12-25
WO2008001931A3 (en) 2009-09-11
EP2431367A3 (en) 2012-07-04
GEP20115359B (en) 2011-12-26
RU2009102515A (ru) 2010-08-10
EP2041123B1 (en) 2012-02-01
IL195947A (en) 2013-07-31
NO20090235L (no) 2009-02-16
US8492430B2 (en) 2013-07-23
CR10564A (es) 2012-06-18
ZA200900154B (en) 2010-03-31
IL195947A0 (en) 2009-09-01
RU2444521C2 (ru) 2012-03-10
JP4401428B2 (ja) 2010-01-20
AU2007265966B2 (en) 2012-05-17
US20120046338A1 (en) 2012-02-23
EP2041123A2 (en) 2009-04-01
JP2009280595A (ja) 2009-12-03
DK2248812T5 (da) 2015-01-26
PT2041123E (pt) 2012-04-09
US20100197761A1 (en) 2010-08-05
US20140080891A1 (en) 2014-03-20
JO2969B1 (en) 2016-03-15
CO6160234A2 (es) 2010-05-20
MA30537B1 (fr) 2009-06-01
JP2009542580A (ja) 2009-12-03
CN103083307A (zh) 2013-05-08
PL2041123T3 (pl) 2012-09-28
EP2743268A3 (en) 2014-10-08
ATE543815T1 (de) 2012-02-15
EP2431367A2 (en) 2012-03-21
DK2248812T3 (da) 2014-03-10
EP2248812A3 (en) 2011-03-16
ME00535B (me) 2011-10-10
CN102731451B (zh) 2015-07-29
HK1131126A1 (en) 2010-01-15
KR101058772B1 (ko) 2011-08-24
TWI354668B (en) 2011-12-21
MX2008016274A (es) 2009-01-15
RS53230B (sr) 2014-08-29
CL2007001873A1 (es) 2008-01-04
TW200811125A (en) 2008-03-01
ES2379661T3 (es) 2012-04-30
JP2012062320A (ja) 2012-03-29
EP2041123B9 (en) 2013-01-02
UA95296C2 (uk) 2011-07-25
CA2838448A1 (en) 2008-01-03
US8598226B2 (en) 2013-12-03
PL2248812T3 (pl) 2014-07-31
KR20090027743A (ko) 2009-03-17
US20100004312A1 (en) 2010-01-07
US7732626B2 (en) 2010-06-08
WO2008001931A2 (en) 2008-01-03
JP5409757B2 (ja) 2014-02-05
CY1114978T1 (el) 2016-12-14
EP2248812A2 (en) 2010-11-10
AR061644A1 (es) 2008-09-10
JP4917634B2 (ja) 2012-04-18
BRPI0713378A2 (pt) 2012-04-03
SI2248812T1 (sl) 2014-04-30
BRPI0713378A8 (pt) 2018-01-02
US20130267589A1 (en) 2013-10-10
CY1112705T1 (el) 2016-02-10
SI2041123T1 (sl) 2012-05-31
HRP20120333T1 (hr) 2012-05-31
EP2743268A2 (en) 2014-06-18
PE20080993A1 (es) 2008-10-06
CA2656003A1 (en) 2008-01-03
CN101616913B (zh) 2013-01-23
ES2450081T3 (es) 2014-03-21
US8088821B2 (en) 2012-01-03

Similar Documents

Publication Publication Date Title
DK2041123T3 (da) Kondenserede cykliske forbindelser.
NL2000581A1 (nl) Aangecondenseerde fenylamidoheterocyclische verbindingen.
BRPI0815717A2 (pt) Compostos de imidazopirazina.
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
FR2909857B1 (fr) Endovalve.
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
CL2007002263S1 (es) Motoneta.
CR10353A (es) Nuevos compuestos.
CL2008000457S1 (es) Motoneta.
BRPI0810203A2 (pt) Compostos peptídeos cíclicos.
CL2007003097S1 (es) Motocicleta.
BRPI0912716A2 (pt) composto.
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
DK2097400T3 (da) Kondenseret, substitueret aminopyrrolidinderivat
BRPI0812460A2 (pt) " compostos orgânicos ".
ITTO20080751A1 (it) Motociclo.
DK2221296T3 (da) Kondenserede indanforbindelser
BRPI0818848A2 (pt) Compostos de 2,3-di-idro-benzofurano
ITCE20060002A1 (it) Patok.
FR2914850B1 (fr) Deambulateur.
ES1061980Y (es) Contenedor-palet.
ES1062074Y (es) Autorefrigerante solar-ecologico.
ITPA20060034A1 (it) Kapot forbir.
ITRA20060010A1 (it) Espositore.
ITAV20060001A1 (it) Generafiume.